Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1

Published:2021-11 Issue: Volume: Page:
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

Nagaraju Ganji Purnachandra^ORCID,Malla Rama Rao^ORCID,Basha Riyaz^ORCID,Motofei Ion G.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research

Reference52 articles.

1. Cancer statistics for the year 2020: An overview;Ferlay;Int. J. Cancer,2021

2. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

3. Tumor microenvironment participates in metastasis of pancreatic cancer;Ren;Mol. Cancer,2018

4. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy;Zhang;Chin. Clin. Oncol.,2019

5. Immune evasion in pancreatic Cancer: from mechanisms to therapy;Martinez-Bosch;Cancers,2018

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment of pancreatic cancer;Molecular Immunology;2024-10

2. Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy;Acta Pharmaceutica Sinica B;2024-09

3. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-08

4. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment;Cancer Letters;2024-07

5. Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma;Scientific Reports;2024-05-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3